FIGURE 3 from Mutant RAS-driven Secretome Causes Skeletal Muscle Defects in Breast Cancer

Impact of PDXs on activation status of select signaling molecules in skeletal muscle. A, Tumors from ER+/PR+ tumor cells reduced AKT phosphorylation in skeletal muscle. B, AKT protein levels in skeletal muscles were not affected by tumors. C, PTEN protein levels in skeletal muscles were not changed by tumors, compared with the control group. D, TNBC-derived PDX upregulated phospho-p38 in skeletal muscle. E, Tumors did not affect total p-38 protein levels in skeletal muscle. Quantification of western blotting was performed using NIH ImageJ software 1.X.